- 503Pharma
- Posts
- Group Stability Study Program — Founding Member Enrollment Open
Group Stability Study Program — Founding Member Enrollment Open
Three USP <797> Category 3 studies. $4,000/year. Limited to 20 pharmacies.
503Pharma .
June 23, 2026
What's Next After GLP-1? Now 100+ Formulas to Build a Resilient Formulary
Sterile and non-sterile, built to current USP 795/797 standards with BUD assignments included. Recent additions include Wolverine blend, KPV, DSIP, PT-141 nasal spray, and many more.
100+ formulations across sterile and non-sterile categories
BUD assignments aligned to USP 795 and 797
Custom formulation requests
Regularly updated as FDA and USP guidance evolves
The members area is free to join. Formula access is a paid feature.
503Pharma community,
A few weeks ago we announced the group lab testing program and asked who was in. The response was strong.
Here’s what we are starting with.
We're launching three (3) USP <797> Category 3 stability studies in Year 1 through 503Pharma. The program details are here.
A single USP <797> Category 3 stability study can cost $10,000 - $20,000 when done alone. We're pooling pharmacies so founding members can get access to three (3) studies for $4,000/year.
Year 1 planned studies:
NAD+ Injectable
BPC-157 Injectable
Third compound chosen by member demand
Important: Before each study launches, we will share the MFR and confirm whether your pharmacy can replicate the formula and required study conditions. The stability data is only useful if your pharmacy can match the final formulation, process, and documentation requirements.
Full details here. Key points:
• Minimum 10 pharmacies to launch — full refund if not met
• Limited to 20 founding members
• This is the lowest price this program will ever be
Reply to this email and we'll send you the enrollment details.
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.